Table 1. Patient characteristics.
| All patients (n=134) | < 20% CD81− Blasts (n=42) | > 20% CD81+ Blasts (n=92) | P-value | |
|---|---|---|---|---|
| Gender [M/F] | 79/56 | 24/18 | 54/38 | 0.83 |
| Age [years]$ | 51.1±16.0 | 46.9±16.4 | 53.0±15.5 | 0.04 |
| WBC [G/L]* | 28 (1-325) | 14 (2-198) | 45(1-325) | 0.02 |
| FAB type | <0.0001 | |||
| M0 | 3% (4/101) | 3% (1/35) | 4% (3/66) | |
| M1 | 22% (22/101) | 14% (5/35) | 26% (17/66) | |
| M2 | 28% (28/101) | 49% (17/35) | 17% (11/66) | |
| M4 | 26% (26/101) | 31% (11/35) | 23% (15/66) | |
| M5 | 19% (19/101) | 3% (1/35) | 27% (18/66) | |
| M6 | 2% (2/101) | 0% (0/35) | 3% (2/66) | |
| Hemoglobin level [g/dL]$ | 9.5±2.2 | 9.5±2.3 | 9.4±2.1 | 0.81 |
| Platelet count [G/L]* | 59 (7-864) | 70 (12-864) | 58 (7-670) | 0.96 |
| Cytogenetic risk, (n/N) | <0.0001 | |||
| Favorable | 11% (14/131) | 28% (12/42) | 2% (2/89) | |
| Intermediate | 75% (98/131) | 55% (23/42) | 84% (75/89) | |
| Unfavorable | 14% (19/131) | 17% (7/42) | 14% (12/89) | |
| FLT3-ITD, (n/N) | 28% (36/129) | 17% (7/41) | 33% (29/88) | 0.06 |
| NPM1 mut, (n/N) | 34% (43/125) | 28% (10/36) | 37% (33/89) | 0.32 |
*
median with range in parenthesis;
$
mean ± SD: standard deviation;
WBC: white blood cell count;
M: male; F: female; NA: not applicable.